#United States #Menlo Park #MyOme #DNA Methylation #SickKids

Introduction

In a significant advancement for genetic testing, MyOme, a clinical whole-genome analysis company based in Menlo Park, California, has formed a collaborative partnership with The Hospital for Sick Children (SickKids) in Toronto, Canada. This collaboration aims to integrate cutting-edge DNA methylation signatures developed by SickKids into MyOme's existing genetic testing platforms. The initiative promises to boost the accuracy and comprehensive nature of rare disease diagnoses.

Partnership Overview

Announced on November 4, 2026, the partnership allows MyOme to license and utilize DNA methylation signatures developed in the laboratory of Dr. Rosanna Weksberg. As a renowned Clinical Geneticist at SickKids and a professor at the University of Toronto, Dr. Weksberg's research has produced over 60 different methylation signatures focused particularly on neurodevelopmental disorders. This partnership is designed to facilitate the integration of these signatures into MyOme's long-read sequencing technology, thereby enhancing clinical testing for rare diseases.

Addressing the Diagnostic Gap

Currently, families seeking diagnoses for rare genetic conditions often endure long waiting periods. Statistics from the Global Commission to End the Diagnostic Odyssey indicate that children with rare diseases wait an average of five years to receive a diagnosis. The existing genetic tests, such as exome or genome sequencing, sometimes fail to provide conclusive insights, leaving many cases unresolved. By incorporating DNA methylation signatures into their testing protocols, MyOme hopes to address this diagnostic gap. Methylation patterns can function like a unique fingerprint, confirming diagnoses or clarifying ambiguous findings from traditional sequencing methods.

The Impact of Long-Read Sequencing

MyOme's long-read sequencing technology stands out because it captures both the DNA sequence and the methylation data in one single test. This means that clinicians can receive both types of information simultaneously, which traditionally would require separate tests. Testing for DNA methylation usually necessitates a different approach, often requiring an additional array-based test after sequencing. By utilizing long-read sequencing, MyOme's testing can provide a more streamlined and efficient diagnostic process.

Collaborative Research Development

According to Dr. Akash Kumar, Chief Medical Officer at MyOme, this agreement with SickKids represents a major enhancement to their testing capabilities. Potential use cases for the methylation signatures include identifying genetic conditions that might otherwise be overlooked during standard sequencing practices. Furthermore, the collaboration will involve the continued research and development of new methylation signatures, expanding the scope of conditions that MyOme’s tests can identify.

Dr. Weksberg outlined how her team's research illustrates that distinct variants in the same gene can leave different methylation signatures. This finding is significant as it can shed light on the diverse clinical presentations observed in children, even when faced with similar genetic mutations.

From Validation to Implementation

The first step in this collaborative effort involves the clinical validation of the methylation signatures. MyOme’s laboratory will conduct tests using known samples to verify the accuracy of the long-read sequencing data in detecting these signatures. Notably, as Methylation analysis is already part of MyOme's rare disease orders, validated signatures can be incorporated seamlessly without requiring new samples or separate orders.

Conclusion

With SickKids’ robust research backing and MyOme’s commitment to integrating innovative genomic analysis, this partnership promises to significantly enrich the genetic testing landscape. Families waiting for answers regarding rare genetic diseases may soon benefit from more precise and informative test results, ultimately closing the diagnostic loop that has left many unanswered cases in the past.

MyOme, having established itself as a leader in whole-genome analysis, continues to pursue opportunities for integrating advanced science into accessible clinical solutions, enabling more families to understand their risk for various diseases effectively.

This collaboration exemplifies the potential of combining clinical research with cutting-edge technology to push the boundaries of what can be achieved in genetic testing.